

**TABLE 3.1** Features of Acute and Chronic Inflammation

| Feature                  | Acute                         | Chronic                               |
|--------------------------|-------------------------------|---------------------------------------|
| Onset                    | Fast: minutes or hours        | Slow: days                            |
| Cellular infiltrate      | Mainly neutrophils            | Monocytes/macrophages and lymphocytes |
| Tissue injury, fibrosis  | Usually mild and self-limited | May be severe and progressive         |
| Local and systemic signs | Prominent                     | Less                                  |

**TABLE 3.2** Disorders Caused by Inflammatory Reactions

| Disorders                           | Cells and Molecules Involved in Injury            |
|-------------------------------------|---|
| <b>Acute</b>                        |   |
| Acute respiratory distress syndrome | Neutrophils                                       |
| Asthma                              | Eosinophils; IgE antibodies                       |
| Glomerulonephritis                  | Antibodies and complement; neutrophils, monocytes |
| Septic shock                        | Cytokines   |
| <b>Chronic</b>                      |   |
| Arthritis                           | Lymphocytes, macrophages; antibodies?             |
| Asthma                              | Eosinophils; IgE antibodies                       |
| Atherosclerosis                     | Macrophages; lymphocytes                          |
| Pulmonary fibrosis                  | Macrophages; fibroblasts                          |

Listed are selected examples of diseases in which the inflammatory response plays a significant role in tissue injury. Some, such as asthma, can present with acute inflammation or a chronic illness with repeated bouts of acute exacerbation. These diseases and their pathogenesis are discussed in relevant chapters.

### Causes of inflammation

|                         |  | Transudate  | Exudate   |
|-------------------------|--|---|---|
| <b>INFECTIONS</b>       | <b>Bacteria, fungi, viruses, parasites<br/>And their toxins</b>                                |   |   |
| <b>NECROSIS</b>         | <b>Ischemia, trauma, physical and<br/>chemical injuries, burns, frostbite,<br/>irradiation</b> | <b>Low protein</b>  | <b>High protein</b>   |
| <b>FOREIGN BODIES</b>   | <b>Splinters, dirt, urate crystals (gout),<br/>Cholesterol crystals (atherosclerosis)</b>      | <b>Low cell content</b>   | <b>Many cells &amp; debris</b>  |
| <b>IMMUNE REACTIONS</b> | <b>Allergies and<br/>autoimmune diseases<br/>(Misdirected inflammatory<br/>response)</b>       | <b>Low specific gravity</b>                                     | <b>Higher specific<br/>gravity</b>  |
|                         |  | <b>Caused by<br/>osmotic/hydrostatic<br/>pressure imbalance</b> | <b>Caused by <u>increased<br/>vascular permeability</u><br/>and denotes<br/>inflammatory reaction</b> |

**TABLE 3.3** Properties of Neutrophils and Macrophages

|  | Neutrophils  | Macrophages   |
|--|--|---|
| Origin   | HSCs in bone marrow  | <ul style="list-style-type: none"> <li>HSCs in bone marrow (in inflammatory reactions)</li> <li>Many tissue-resident macrophages: stem cells in yolk sac or fetal liver (early in development)</li> </ul> |
| Life span in tissues   | 1–2 days   | Inflammatory macrophages: days or weeks<br>Tissue-resident macrophages: years   |
| Responses to activating stimuli  | Rapid, short-lived, mostly degranulation and enzymatic activity      | More prolonged, slower, often dependent on new gene transcription   |
| <ul style="list-style-type: none"> <li>Reactive oxygen species</li> </ul>        | Rapidly induced by assembly of phagocyte oxidase (respiratory burst) | Less prominent  |
| <ul style="list-style-type: none"> <li>Nitric oxide</li> </ul>                   | Low levels or none   | Induced following transcriptional activation of iNOS  |
| <ul style="list-style-type: none"> <li>Degranulation</li> </ul>                  | Major response; induced by cytoskeletal rearrangement                | Not prominent   |
| <ul style="list-style-type: none"> <li>Cytokine production</li> </ul>            | Low levels or none   | Major functional activity, requires transcriptional activation of cytokine genes  |
| <ul style="list-style-type: none"> <li>NET formation</li> </ul>                  | Rapidly induced, by extrusion of nuclear contents                    | No  |
| <ul style="list-style-type: none"> <li>Secretion of lysosomal enzymes</li> </ul> | Prominent  | Less  |

HSC, Hematopoietic stem cells; iNOS, inducible nitric oxide synthase; NET, neutrophil extracellular traps.

This table lists the major differences between neutrophils and macrophages. The reactions summarized above are described in the text. Note that the two cell types share many features, such as phagocytosis, ability to migrate through blood vessels into tissues, and chemotaxis.



**NOT REQUIRED**

**TABLE 3.4** Endothelial and Leukocyte Adhesion Molecules

| Family   | Molecule           | Distribution  | Ligand  |
|----------|--------------------|---|---|
| Selectin | L-selectin (CD62L) | Neutrophils, monocytes<br>T cells (naïve and central memory)<br>B cells (naïve)   | Sialyl-Lewis X/PNAd on GlyCAM-1, CD34, MAdCAM-1, others; expressed on endothelium (HEV)                           |
|          | E-selectin (CD62E) | Endothelium activated by cytokines (TNF, IL-1)                                    | Sialyl-Lewis X (e.g., CLA) on glycoproteins; expressed on neutrophils, monocytes, T cells (effector, memory)      |
|          | P-selectin (CD62P) | Endothelium activated by cytokines (TNF, IL-1), histamine, or thrombin; platelets | Sialyl-Lewis X on PSGL-1 and other glycoproteins; expressed on neutrophils, monocytes, T cells (effector, memory) |
| Integrin | LFA-1 (CD11aCD18)  | Neutrophils, monocytes, T cells (naïve, effector, memory)                         | ICAM-1 (CD54), ICAM-2 (CD102); expressed on endothelium (upregulated on activated endothelium)                    |
|          | MAC-1 (CD11bCD18)  | Monocytes, DCs  | ICAM-1 (CD54), ICAM-2 (CD102); expressed on endothelium (upregulated on activated endothelium)                    |
|          | VLA-4 (CD49aCD29)  | Monocytes<br>T cells (naïve, effector, memory)                                    | VCAM-1 (CD106); expressed on endothelium (upregulated on activated endothelium)                                   |
|          | α4β7 (CD49D/CD29)  | Monocytes<br>T cells (gut homing naïve effector, memory)                          | VCAM-1 (CD106), MAdCAM-1; expressed on endothelium in gut and gut-associated lymphoid tissues                     |
| Ig       | CD31               | Endothelial cells, leukocytes   | CD31 (homotypic interaction)  |

CLA, Cutaneous lymphocyte antigen-1; GlyCAM-1, glycan-bearing cell adhesion molecule-1; HEV, high endothelial venule; ICAM, intercellular adhesion molecule; Ig, immunoglobulin; IL-1, interleukin-1; MAdCAM-1, mucosal adhesion cell adhesion molecule-1; PSGL-1, P-selectin glycoprotein ligand-1; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule.

**CHEMOATTRACTANTS** group → An example of it

|                         |                  |
|-------------------------|------------------|
| Bacterial Products      | Peptides (N-...) |
| Cytokines               | Chemokine family |
| Complement system       | C5a              |
| Lipoxygenase pathway AA | LTB4             |

**WBCs infiltrates in tissue**

|   |                               |
|---|-------------------------------|
| Neutrophils (PMNs)                      | 6-24 hours, acute phase       |
| Macrophages, lymphocytes & plasma cells | 24-48 hours and then may stay |
| <u>Allergic reactions</u>               | Eosinophils                   |

فَاذْكُرُونِي  
أَذْكُرْكُمْ

## Termination of IR

**Mediators are produced in rapid bursts**

**Release is stimulus dependent**

**Short half-lives**

**Degradation after release**

**PMNs short life (apoptosis)**

**Stop signals production (TGF- $\beta$ , IL-10)**

**Neural inhibitors (cholinergic): inhibits TNF**

## Mediators of acute inflammation

|                       |                        |
|-----------------------|------------------------|
| Vasoactive amines     | Histamine, serotonin   |
| Lipid products        | PGs and LTs            |
| Cytokines             | IL, TNF and Chemokines |
| Complement activation | C1-9                   |

TABLE 3.5 Principal Mediators of Inflammation

| Mediator                    | Source                                     | Action  |
|-----------------------------|--|---|
| Histamine                   | Mast cells, basophils, platelets           | Vasodilation, increased vascular permeability, endothelial activation   |
| Prostaglandins              | Mast cells, leukocytes                     | Vasodilation, pain, fever   |
| Leukotrienes                | Mast cells, leukocytes                     | Increased vascular permeability, chemotaxis, leukocyte adhesion, and activation   |
| Cytokines (TNF, IL-1, IL-6) | Macrophages, endothelial cells, mast cells | Local: endothelial activation (expression of adhesion molecules). Systemic: fever, metabolic abnormalities, hypotension (shock) |
| Chemokines                  | Leukocytes, activated macrophages          | Chemotaxis, leukocyte activation  |
| Platelet-activating factor  | Leukocytes, mast cells                     | Vasodilation, increased vascular permeability, leukocyte adhesion, chemotaxis, degranulation, oxidative burst                   |
| Complement                  | Plasma (produced in liver)                 | Leukocyte chemotaxis and activation, direct target killing (membrane attack complex), vasodilation (mast cell stimulation)      |
| Kinins                      | Plasma (produced in liver)                 | Increased vascular permeability, smooth muscle contraction, vasodilation, pain  |

\*Things not mentioned in the next page are highlighted

I'm gonna divide the last table into two  
trying to simplify it :)



| Mediators according to source |  |
|-------------------------------|--|
| Mast cells                    | Histamine, PGs, LTs, cytokines, platelet activating factor |
| Basophils                     | Histamine  |
| Platelets                     | Histamine  |
| Leukocytes                    | PGs, LTs, chemokines, platelet activating factor           |
| Macrophages                   | Cytokines, chemokines (activated)                          |
| Endothelial cells             | Cytokines  |
| Plasma                        | Complement, kinins   |

| Mediators according to action<br>(Actions in common) |   |
|--|---|
| Vasodilation   | Histamine, PGs (PGI <sub>2</sub> , PGE <sub>1</sub> , PGE <sub>2</sub> , PGD <sub>2</sub> ), kinins, complement, platelet activating factor |
| Increased vascular permeability                      | Histamine, LTs (C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub> ), kinins, platelet activating factor                                      |
| Endothelial activation                               | Histamine, cytokines  |
| Chemotaxis   | LTs (LTB <sub>4</sub> ), chemokines, complement, platelet activating factor   |
| Pain   | PGs, kinins   |
| Fever  | PGs, cytokines  |
| Vasoconstriction                                     | Thromboxane A <sub>2</sub> , LTs (C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub> )  |
| Smooth muscle contraction                            | PGs (C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub> ), kinins   |

**TABLE 3.6** Principal Actions of Arachidonic Acid Metabolites in Inflammation

| Action                          | Eicosanoid   |
|---------------------------------|--|
| Vasodilation                    | Prostaglandins PGI <sub>2</sub> (prostacyclin), PGE <sub>1</sub> , PGE <sub>2</sub> , PGD <sub>2</sub> |
| Vasoconstriction                | Thromboxane A <sub>2</sub> , leukotrienes C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub>             |
| Increased vascular permeability | Leukotrienes C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub>  |
| Chemotaxis, leukocyte adhesion  | Leukotriene B <sub>4</sub>   |
| Smooth muscle contraction       | Prostaglandins PGC <sub>4</sub> , PGD <sub>4</sub> , PGE <sub>4</sub>                                  |

**TABLE 3.7** Cytokines in Inflammation

| Cytokine  | Principal Sources   | Principal Actions in Inflammation  |
|---|---|--|
| <b>In Acute Inflammation</b>  |   |  |
| TNF   | Macrophages, mast cells, T lymphocytes                                      | Stimulates expression of endothelial adhesion molecules and secretion of other cytokines; systemic effects |
| IL-1  | Macrophages, endothelial cells, some epithelial cells                       | Similar to TNF; greater role in fever  |
| IL-6  | Macrophages, other cells  | Systemic effects (acute phase response)  |
| Chemokines  | Macrophages, endothelial cells, T lymphocytes, mast cells, other cell types | Recruitment of leukocytes to sites of inflammation; migration of cells in normal tissues                   |
| IL-17   | T lymphocytes   | Recruitment of neutrophils and monocytes   |
| <b>In Chronic Inflammation</b>  |   |  |
| IL-12   | Dendritic cells, macrophages  | Increased production of IFN- $\gamma$  |
| IFN- $\gamma$   | T lymphocytes, NK cells   | Activation of macrophages (increased ability to kill microbes and tumor cells)                             |
| IL-17   | T lymphocytes   | Recruitment of neutrophils and monocytes   |
| <p>The most important cytokines involved in inflammatory reactions are listed. Many other cytokines may play lesser roles in inflammation. There is also considerable overlap between the cytokines involved in acute and chronic inflammation. Specifically, all the cytokines listed under acute inflammation may also contribute to chronic inflammatory reactions.</p> <p><i>IFN-<math>\gamma</math></i>, Interferon-<math>\gamma</math>; <i>IL-1</i>, interleukin-1; <i>NK</i>, natural killer; <i>TNF</i>, tumor necrosis factor.</p> |   |  |

**TABLE 3.8** Role of Mediators in Different Reactions of Inflammation

| Reaction of Inflammation                         | Principal Mediators  |
|--|--|
| Vasodilation                                     | Histamine  |
|  | Prostaglandins   |
| Increased vascular permeability                  | Histamine  |
|  | C3a and C5a (by liberating vasoactive amines from mast cells, other cells) |
|  | Leukotrienes C <sub>4</sub> , D <sub>4</sub> , E <sub>4</sub>              |
| Chemotaxis, leukocyte recruitment and activation | TNF, IL-1  |
|  | Chemokines   |
|  | C3a, C5a   |
|  | Leukotriene B <sub>4</sub>   |
| Fever  | IL-1, TNF  |
|  | Prostaglandins   |
| Pain   | Prostaglandins   |
|  | Bradykinin   |
| Tissue damage                                    | Lysosomal enzymes of leukocytes  |
|  | Reactive oxygen species  |



### Morphology of acute inflammation

|                         |   |
|-------------------------|---|
| <b>Edema</b>            | <b>Fluid and proteins in interstitium</b> |
| <b>Redness</b>          | <i>rubor</i>                              |
| <b>Warmth</b>           | <i>calor</i>                              |
| <b>Swelling</b>         | <i>tumor</i>                              |
| <b>Loss of function</b> | <i>Functio laesa</i>                      |
| <b>Pain</b>             | <i>dolor</i>                              |

### Causes of chronic inflammation

|   |   |
|---|---|
| <b>Persistent infections</b>  | <b>Mycobacteria (TB), viruses, fungi, parasites. Delayed hypersensitivity reaction. Granulomatous inflammation.</b> |
| <b>Hypersensitivity diseases</b>                                    | <b>RA, asthma, MS. May end in fibrosis of end organs</b>  |
| <b>Prolonged exposure to toxic agents (exogenous or endogenous)</b> | <b>Silica (silicosis)<br/>Atherosclerosis (cholesterol)</b>   |
| <b>Other associated diseases</b>                                    | <b>Alzheimer's, Metabolic syndrome of DM</b>  |

## CD4+ T cells


|             |   |
|-------------|---|
| <b>Th1</b>  | <b>INF-<math>\gamma</math>, activates Macs in classic pathway</b>                 |
| <b>Th2</b>  | <b>IL-4, IL-5 &amp; IL-13; activates eosinophils and Macs alternative pathway</b> |
| <b>Th17</b> | <b>IL-17, induce chemokines secretion and recruits PMNs</b>                       |

**TABLE 3.9** Examples of Diseases With Granulomatous Inflammation

| Disease                                    | Cause   | Tissue Reaction  |
|--|---|--|
| Tuberculosis                               | <i>Mycobacterium tuberculosis</i>   | Caseating granuloma (tubercle): focus of activated macrophages (epithelioid cells), rimmed by fibroblasts, lymphocytes, histiocytes, occasional Langhans giant cells; central necrosis with amorphous granular debris; acid-fast bacilli |
| Leprosy                                    | <i>Mycobacterium leprae</i>   | Acid-fast bacilli in macrophages; noncaseating granulomas  |
| Syphilis                                   | <i>Treponema pallidum</i>   | Gumma: microscopic to grossly visible lesion, enclosing wall of macrophages; plasma cell infiltrate; central cells are necrotic without loss of cellular outline; organisms difficult to identify in tissue                              |
| Cat-scratch disease                        | Gram-negative bacillus  | Rounded or stellate granuloma containing central granular debris and recognizable neutrophils; giant cells uncommon  |
| Sarcoidosis                                | Unknown etiology  | Noncaseating granulomas with abundant activated macrophages  |
| Crohn disease (inflammatory bowel disease) | Immune reaction against undefined gut microbes and, possibly, self antigens | Occasional noncaseating granulomas in the wall of the intestine, with dense chronic inflammatory infiltrate  |

## Systemic effects of inflammation

|                             |   |
|-----------------------------|---|
| Fever (1-4 C) elevation     | Exogenous pyrogens (LPS) & endogenous pyrogens (IL-1 & TNF). All induce PGE2 secretion          |
| Acute phase proteins        | CRP, SAA, ESR, Hecpidin   |
| Leukocytosis (increase WBC) | 15-20 K if more than 40 (leukemoid reaction), left shift  |
| Others                      | Tachycardia, Increase BP, Chills, Rigors, decreased sweating, anorexia, somnolence, and malaise |



|| pain = <sup>(PGE2)</sup> PGs + Kinins

Fever = PGs + cytokines

→ pain + Fever = PGs

|| Chemokines → Leukocyte activation

platelet activating factor → Leukocyte adhesion

Leukotriens → Leukocyte activation & adhesion

|| PGs → Vasodilation

LTs → ↑ vascular permeability

Histamine + platelet activating factor + Kinins → Vasodilation & ↑ vascular permeability

|| Cytokines may be located in endothelial cells, so they contribute to leukocyte adhesion there.

